title: [Pharmacokinetic and clinical studies on cefodizime in the field of obstetrics and gynecology].
abstract: We have conducted pharmacokinetic and clinical trials of a new cephem derivative, cefodizime (THR-221, CDZM), and obtained the following results. 1. We administered CDZM to 4 cases with abdominal simple hysterectomy due to myoma uteri at a dose level of 1 g by drip intravenous injection and studied average levels of transfer measured at various locations in the uterine tissues and adnexa at an average of 2 hours after administration. CDZM level was highest in the oviduct, 13.7 micrograms/g (ratio with respect to the uterine arterial blood: 91.3%), followed by the ovary, portio vaginalis, cervix uteri and endometrium, and was lowest in the myometrium, 8.3 micrograms/g (55.3%). CDZM concentrations were higher than 6.04 micrograms/g in any tissues. 2. To study CDZM transfer to pelvic cavity fluid, we administered CDZM to 5 cases with total hysterectomy due to cervical cancer of uteri at a dose level of 2 g using drip intravenous injection. The drug was transferred at high levels to the pelvic cavity fluid. A level of 11.7 micrograms/ml was observed at 3 hours after injection. The drug levels in the pelvic cavity fluid were maintained continuously higher levels than those of venous blood. These concentrations in the uterine tissues and pelvic cavity fluid were higher than the MIC against many strains of Gram-positive and Gram-negative bacteria, hence we considered them to be therapeutically effective concentrations. 3. Eleven cases of gynecological infections receiving in totals of 8 to 48 g of CDZM demonstrated "excellent" results in 3 cases, "good" in 8 cases. Eight strains of organisms were isolated from 10 cases.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Okayama University.
authors.forename: Y
authors.initials: Y
authors.lastname: Nakagiri
authors.forename: H
authors.initials: H
authors.lastname: Okuda
authors.forename: K
authors.initials: K
authors.lastname: Niida
authors.forename: T
authors.initials: T
authors.lastname: Kondoh
authors.forename: T
authors.initials: T
authors.lastname: Sanoh
authors.forename: M
authors.initials: M
authors.lastname: Nishi
authors.forename: K
authors.initials: K
authors.lastname: Yamashita
authors.forename: Y
authors.initials: Y
authors.lastname: Suzuki
authors.forename: K
authors.initials: K
authors.lastname: Eguchi
authors.forename: K
authors.initials: K
authors.lastname: Sekiba
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000188:drug therapy*; D002439:Cefotaxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004341:Drug Evaluation; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D005836:Genitalia, Female / Q000378:metabolism*; D006801:Humans; D007044:Hysterectomy; D007262:Infusions, Intravenous; D007889:Leiomyoma / Q000378:metabolism / Q000601:surgery; D008875:Middle Aged; D011184:Postoperative Period; D002583:Uterine Cervical Neoplasms / Q000378:metabolism / Q000601:surgery; D014594:Uterine Neoplasms / Q000378:metabolism / Q000601:surgery
chemical_list: D002439:Cefotaxime; C033356:cefodizime